Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers

Atea begins phase 1 trial of hepatitis E treatment AT-587

Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class…

AT-587 was 30- to 150-fold more potent in vitro than sofosbuvir and ribavirin; its Phase 1 study will assess safety, tolerability and pharmacokinetics.

CHP investigates a case of human infection of rat Hepatitis E virusThe Centre for Health Protection

CHP investigates a case of human infection of rat Hepatitis E virusThe Centre for Health Protection

Discover how Hepatitis E viruses dynamically mutate during early acute infection, using transcomplementation to survive and adapt within the host.

Knowing how viruses change in the initial weeks of an infection can provide important information about their adaptability.

Knowing how viruses change in the initial weeks of an infection can provide important information about their adaptability. Researchers from the Departments of Molecular & Medical Virology and Translational …

Atea Pharmaceuticals Inc. recently presented preclinical data on two of its compounds, AT-2490 and AT-587, which have shown promising antiviral potential for treating hepatitis E virus infection.

Find out what DAFM's landholding is in your county

Hepatitis E virus genes have been identified in pigmeat products in several countries, including Ireland, according to the FSAI

WHO fact sheet on hepatitis E, how it is transmitted, symptoms, prevention, testing and diagnosis, treatment and WHO activities.

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. This fact sheet provides information about transmission, symptoms, diagnosis, treatment, prevention and WHO's work to support prevention and treatment.

Wastewater surveillance in Ahmedabad, Gandhinagar, Vadodara and Rajkot detected 305 virus species, showing early warning potential for Covid, hepatitis and GI viruses.

Food safety fact sheet provides key facts and information on major foodborne illnesses, causes, evolving world and food safety and WHO response.

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E VirusBOSTON, May 27, 2026 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral […]

Most HCV patients juggle drugs. Phase 1 data show Atea’s BEM/RZR works with PPIs and statins, while AT-587 shows HEV activity in lab and animal tests.

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting…

Hepatitis E vaccine safety data show no detected rise in fetal loss during pregnancy. Read more.